Cargando…
Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment
Targeting glutamine catabolism has been attracting more research attention on the development of successful cancer therapy. Catalytic enzymes such as glutaminase (GLS) in glutaminolysis, a series of biochemical reactions by which glutamine is converted to glutamate and then alpha-ketoglutarate, an i...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570367/ https://www.ncbi.nlm.nih.gov/pubmed/33721588 http://dx.doi.org/10.1016/j.cbpa.2021.01.006 |
_version_ | 1784594824480948224 |
---|---|
author | Shen, Yao-An Chen, Chi-Long Huang, Yi-Hsuan Evans, Emily Elizabeth Cheng, Chun-Chia Chuang, Ya-Jie Zhang, Cissy Le, Anne |
author_facet | Shen, Yao-An Chen, Chi-Long Huang, Yi-Hsuan Evans, Emily Elizabeth Cheng, Chun-Chia Chuang, Ya-Jie Zhang, Cissy Le, Anne |
author_sort | Shen, Yao-An |
collection | PubMed |
description | Targeting glutamine catabolism has been attracting more research attention on the development of successful cancer therapy. Catalytic enzymes such as glutaminase (GLS) in glutaminolysis, a series of biochemical reactions by which glutamine is converted to glutamate and then alpha-ketoglutarate, an intermediate of the tricarboxylic acid (TCA) cycle, can be targeted by small molecule inhibitors, some of which are undergoing early phase clinical trials and exhibiting promising safety profiles. However, resistance to glutaminolysis targeting treatments has been observed, necessitating the development of treatments to combat this resistance. One option is to use synergy drug combinations, which improve tumor chemotherapy’s effectiveness and diminish drug resistance and side effects. This review will focus on studies involving the glutaminolysis pathway and diverse combination therapies with therapeutic implications. |
format | Online Article Text |
id | pubmed-8570367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
record_format | MEDLINE/PubMed |
spelling | pubmed-85703672021-11-05 Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment Shen, Yao-An Chen, Chi-Long Huang, Yi-Hsuan Evans, Emily Elizabeth Cheng, Chun-Chia Chuang, Ya-Jie Zhang, Cissy Le, Anne Curr Opin Chem Biol Article Targeting glutamine catabolism has been attracting more research attention on the development of successful cancer therapy. Catalytic enzymes such as glutaminase (GLS) in glutaminolysis, a series of biochemical reactions by which glutamine is converted to glutamate and then alpha-ketoglutarate, an intermediate of the tricarboxylic acid (TCA) cycle, can be targeted by small molecule inhibitors, some of which are undergoing early phase clinical trials and exhibiting promising safety profiles. However, resistance to glutaminolysis targeting treatments has been observed, necessitating the development of treatments to combat this resistance. One option is to use synergy drug combinations, which improve tumor chemotherapy’s effectiveness and diminish drug resistance and side effects. This review will focus on studies involving the glutaminolysis pathway and diverse combination therapies with therapeutic implications. 2021-03-12 2021-06 /pmc/articles/PMC8570367/ /pubmed/33721588 http://dx.doi.org/10.1016/j.cbpa.2021.01.006 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article unde r the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Article Shen, Yao-An Chen, Chi-Long Huang, Yi-Hsuan Evans, Emily Elizabeth Cheng, Chun-Chia Chuang, Ya-Jie Zhang, Cissy Le, Anne Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment |
title | Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment |
title_full | Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment |
title_fullStr | Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment |
title_full_unstemmed | Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment |
title_short | Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment |
title_sort | inhibition of glutaminolysis in combination with other therapies to improve cancer treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570367/ https://www.ncbi.nlm.nih.gov/pubmed/33721588 http://dx.doi.org/10.1016/j.cbpa.2021.01.006 |
work_keys_str_mv | AT shenyaoan inhibitionofglutaminolysisincombinationwithothertherapiestoimprovecancertreatment AT chenchilong inhibitionofglutaminolysisincombinationwithothertherapiestoimprovecancertreatment AT huangyihsuan inhibitionofglutaminolysisincombinationwithothertherapiestoimprovecancertreatment AT evansemilyelizabeth inhibitionofglutaminolysisincombinationwithothertherapiestoimprovecancertreatment AT chengchunchia inhibitionofglutaminolysisincombinationwithothertherapiestoimprovecancertreatment AT chuangyajie inhibitionofglutaminolysisincombinationwithothertherapiestoimprovecancertreatment AT zhangcissy inhibitionofglutaminolysisincombinationwithothertherapiestoimprovecancertreatment AT leanne inhibitionofglutaminolysisincombinationwithothertherapiestoimprovecancertreatment |